Bortezomib
- PDF / 141,378 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 31 Downloads / 146 Views
1
S
Acute pneumonitis: case report A man in his mid-50s [age not clearly stated] developed acute pneumonitis during treatment with bortezomib. He subsequently died. The man, who had relapsed multiple myeloma, presented with renal failure. He received five doses of IV bortezomib 2.1mg, together with dexamethasone, on day 0, day 3, day 7, day 10, and day 21 of therapy. Between 3 and 6 days after all but his fourth dose, he developed episodes of fever, hypoxia and radiographic interstitial changes that lasted 3–6 days. In each episode he experienced dyspnoea and cough, and reduced oxygen saturation. Chest x-rays and CT pulmonary angiogram revealed bi-basal reticular shadowing, pleural effusions and extensive nodular interstitial shadowing, consistent with pneumonitis. The man received piperacillin/tazobactam, bronchodilators and diuretics. However, he demonstrated no symptomatic improvement. After the third episode of pneumonitis, he received cotrimoxazole, and did not experience a pneumonic episode following the fourth bortezomib dose. Bortezomib was withdrawn after the fifth dose, and his respiratory function returned to baseline. However, 28 days later, he developed Clostridium difficile sepsis and died. O’Riordan D, et al. Breathless on bortezomib. BMJ Case Reports 2011: [3 pages], 18 Aug 2011. Available from: URL: http://dx.doi.org/10.1136/bcr.03.2011.4028 803062653 United Kingdom
0114-9954/10/1378-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 19 Nov 2011 No. 1378
Data Loading...
